Curevo, Inc.
Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines. They focus on one unmet medical need at a time, aiming to bring effective and better-tolerated vaccines to market quickly and efficiently. Their focus includes adjuvanted subunit vaccines for shingles and chickenpox, with ongoing clinical trials and research to improve vaccine accessibility and tolerability. The company emphasizes tolerability, efficacy, and accessibility in vaccine development, aiming to reduce disease burden globally through innovative vaccine solutions.
Industries
Nr. of Employees
small (1-50)
Curevo, Inc.
18911 N Creek Pkwy #150, Bothell, WA 98011
Patents
Products
Investigational adjuvanted subunit vaccine candidate (varicella zoster)
A non-live, adjuvanted protein subunit vaccine candidate targeting varicella zoster glycoprotein antigen(s), developed for prevention of shingles in adults and evaluation for prevention of chickenpox in pediatric and immunocompromised populations. Formulation and processes were developed with scale-up and deployable manufacturing in mind.
Investigational adjuvanted subunit vaccine candidate (varicella zoster)
A non-live, adjuvanted protein subunit vaccine candidate targeting varicella zoster glycoprotein antigen(s), developed for prevention of shingles in adults and evaluation for prevention of chickenpox in pediatric and immunocompromised populations. Formulation and processes were developed with scale-up and deployable manufacturing in mind.
Expertise Areas
- Clinical trial management and biostatistics
- Adjuvant chemistry and formulation
- Protein subunit vaccine R&D
- Immunogenicity assessment and immune monitoring
Key Technologies
- Adjuvanted protein subunit vaccine platforms
- TLR4-agonist adjuvant chemistry
- Humoral immunoassays (antibody titer, GMC)
- Cellular immunoassays (T‑cell assays, immune monitoring)
News & Updates
Curevo Vaccine announces the enrollment of the first patients in a Phase 2 extension trial of its investigational shingles vaccine, amezosvatein, targeting safety and immune response in adults aged 50 and over.
Curevo announced it has raised $110 million to support the clinical development of its shingles vaccine candidate, amezosvatein, which has shown excellent immunogenicity and improved tolerability in Phase 2 studies.
Curevo reported positive immunogenicity and safety data from its Phase 2 trial of amezosvatein, showing non-inferior immune response compared to Shingrix and lower reactogenicity.
Curevo's Phase 2 trial results show that amezosvatein elicits a robust immune response non-inferior to Shingrix, with better tolerability, and is progressing towards Phase 3 trials.
Curevo announced it will present data at the upcoming J.P. Morgan Healthcare Conference, highlighting its progress in vaccine development.
Recognition for excellence in the Bothell community.
Curevo Vaccine announces the enrollment of the first patients in a Phase 2 extension trial of its investigational shingles vaccine, amezosvatein, targeting safety and immune response in adults aged 50 and over.
Curevo announced it has raised $110 million to support the clinical development of its shingles vaccine candidate, amezosvatein, which has shown excellent immunogenicity and improved tolerability in Phase 2 studies.
Curevo reported positive immunogenicity and safety data from its Phase 2 trial of amezosvatein, showing non-inferior immune response compared to Shingrix and lower reactogenicity.
Curevo's Phase 2 trial results show that amezosvatein elicits a robust immune response non-inferior to Shingrix, with better tolerability, and is progressing towards Phase 3 trials.
Curevo announced it will present data at the upcoming J.P. Morgan Healthcare Conference, highlighting its progress in vaccine development.
Recognition for excellence in the Bothell community.